Orbital metastases are rare. Breast cancer represents the first etiology to be evoked in carcinomas. We report a rare case of a young 43-year-old patient who developed significant orbital metastasis 2 months after the end of adjuvant treatment for triple-negative breast cancer. Good partial response was shown with an improvement of symptoms under chemotherapy (docetaxel combined with carboplatin), zoledronic acid and palliative radiotherapy. The patient quickly progressed in the pulmonary, hepatic and lymph nodes with mucocutaneous jaundice related to hepatic dysfunction after which she died within 20 days. Different etiologies are responsible for the orbital tumor syndrome. This orbital metastasis may constitute an inaugural mode of expression of the tumor affection. The frequency of metastases of breast cancer overexpressing estrogen receptor can be explained biologically by the presence of estrogen receptors in hormone acting as target choroid tissue steroids for lacrimal secretion. On the other hand, in triple-negative breast cancer, since the hormone receptors are negative, the pathophysiology of these orbital metastases remains unknown. At this stage, the treatment remains palliative, including radiotherapy, chemotherapy, and bisphosphonates, and the prognosis is grim.

HIV infection greatly increases the risk of developing lymphoma. NHL is present in approximately 3% of the HIV-positive population at the time of their HIV diagnosis. Twenty percent of HIV-positive patients develop NHL. Risk factors for an association of the NHL with HIV include: low CD4 T cell count, high viral load, age, and male. We report the case of a 35-year-old mother of three children having a history of the death of the husband following the neurological complications of AIDS, the patient was subsequently diagnosed with HIV + and then placed on retroviral treatment. After 6 months the patient reported a breast swelling with pelvic pain, a breast biopsy performed showing a large B-cell NHL. The extension assessment reveals localizations: mammary, bilateral ovarian and adrenal right of a lymphomatous process, the BOM is normal and the CD4 rate is 517 / mm3. CHOP-type systemic chemotherapy with intrathecal chemotherapy has been initiated. The post-treatment evaluation was in favor of a complete clinical and radiological response. The prognosis of patients with AIDS-related lymphoma is associated with the stage of the disease, extraganglionic involvement including bone marrow, CD4 cell count, and performance status. Median survival varies from 8 to 20 months, which remains much lower than that of non-HIV-associated lymphomas.